Spinifex Pharmaceuticals Closes $19M VC Round

Australia’s Spinifex Pharmaceuticals has closed its Series B round after adding an additional AU$6.25 million ($6.5 million) from GBS Venture Partners, Brandon Capital Partners, Uniseed Management and UniQuest. The total amount raised in the round was $19 million. The money will help fund the development of Spinifex’s pain management drug.

23 August 2011•4 mins read
Feature image
LinkedInXEmail
LinkedInXEmail